• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Investing

Pfizer v Medical Properties: Covid-19 Vaccines give Pfizer an edge

by February 20, 2022
by February 20, 2022

Pfizer Inc

Pfizer Inc. (NYSE:PFE) is a company that manufactures and markets biopharmaceutical products worldwide. They provide medications for various conditions including heart disease, diabetes mellitus type 2, viral infections such as those caused by influenza A virus subtype H1N1 or enteroviruses, and cancer treatments involving chemotherapy agents.

Pfizer also provides vaccines against bacterial pneumonia, meningococcal diseases, Covid 19, strep throat among others. The company is a leader in contract manufacturing. They provide services to wholesalers, hospitals, retailers, disease prevention and control centres, and government agencies.

Medical Properties Trust Inc

Medical Properties Trust, Inc. (NYSE:MPW) is a real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. The company has grown gradually to become one of the world’s largest owners, with approximately 431 hospitals across nine countries in four continents.

This growth can be attributed largely due to their financing model which facilitates purchases or recapitalizations while also allowing operators to unlock the value buried within these properties so they may spend money wisely for improvements like technology upgrades but most importantly investing heavily into operations!

Which one is a better buy?

Pfizer and Medical Properties are both awesome buys at current prices. They are both in markets that tend to perform well regardless of market conditions. Now that rates are going up, these two make for good defensive stocks.

However, of the two, Pfizer makes for a better buy. That’s because the COVID-19 vaccine has given Pfizer not just a boost in revenues. Pfizer is also one of the world’s largest pharmaceutical companies and always a product in the pipeline. This pretty much guarantees its revenue growth not just in 2022 but for years to come.

The post Pfizer v Medical Properties: Covid-19 Vaccines give Pfizer an edge appeared first on Invezz.

0 comment
0
FacebookTwitterPinterestEmail

previous post
D.C.’s “Best Information Available” Charade
next post
What An Economist Knows About Crony Vaccines

Related Posts

SDY stock: Is this dividend aristocrat ETF a...

May 30, 2023

3 overbought US sectors to watch in the...

May 30, 2023

ZIM Integrated Shipping stock price: the plot thickens

May 30, 2023

IDS share price: Here’s why I’d never buy...

May 30, 2023

Rolls-Royce share price outlook as volatility, volume slips

May 30, 2023

Rivian stock price forecast: Here’s why I’m buying...

May 30, 2023

Samsung vs TSMC stock: Susquehanna analyst picks a...

May 29, 2023

Nasdaq statistics in 2023

May 29, 2023

Professor Jeremy Siegel on AI stocks: ‘it’s not...

May 29, 2023

Debt ceiling deal: will the U.S. stocks rally...

May 29, 2023

Recent Posts

  • An Insider Untangles the Causes of the Financial Crisis in American Cities

    October 1, 2023
  • TSR Market Update: Bluetooth Low Energy Market

    October 1, 2023
  • Everynet Announces General Availability of LoRaWAN Connectivity Using AWS IoT Core for LoRaWAN

    October 1, 2023
  • Why is Baby Formula Kept Under Lock and Key?

    September 30, 2023
  • Inflation was Worse than We Thought

    September 30, 2023
  • Let’s Stop Pretending IoT Is Easy

    September 29, 2023

Editors’ Picks

  • 1

    Nvidia Corporation earnings beat not sufficient to boost stock – Is it a good buy?

    February 18, 2022
  • 2

    2 Canadian marijuana stocks to keep a close eye on

    February 5, 2022
  • 3

    Is it too late to sell Biogen stock after losing an appeal on its multiple sclerosis drug?

    November 30, 2021
  • 4

    Headed for Insolvency: Biden Administration Increases US Obligations Worldwide

    May 29, 2022
  • 5

    The General Welfare

    November 4, 2021
  • 6

    The IMF Should Be Eliminated, Not Expanded

    October 12, 2021
  • 7

    Micron Technology shares are trading lower after-hours: here’s why

    September 29, 2021
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Categories

  • Economy (2,131)
  • Editor's Pick (727)
  • Investing (5,549)
  • Stock (10)
About Us Terms & Conditions Privacy Policy Email WhiteListing Contact Us

Disclaimer: Portfolioperformancetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2023 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick

Read alsox

Ex-Visa exec Michele Quintaglie joins Algorand as...

September 21, 2022

Manchester United stock prediction after outperforming FQ1...

November 17, 2021

Target warns of a further hit to...

June 7, 2022